A prespecified SELECT analysis finds semaglutide's cardiovascular benefit is largely independent of weight loss, with only a third mediated by waist reduction. PICO summary and commentary.
SYNCHRONIZE-1 reports baseline characteristics of a phase 3 survodutide obesity trial; efficacy results are pending. PICO summary and expert commentary.
A SURMOUNT-5 analysis finds tirzepatide and semaglutide improve physical quality of life in obesity, with neither improving mental-health scores. PICO summary and expert commentary.
The phase 2b IMPACT trial finds weekly pemvidutide resolves MASH but does not significantly improve fibrosis at 24 weeks. PICO summary and expert commentary.
In patients with type 2 diabetes (T2D), once-weekly semaglutide significantly increased the risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) compared to non-exposure, doubling the five-year hazard ratio (HR), though it was associated with improved glycaemic control and other cardiometabolic benefits.
In adults with diabetes mellitus but no evident cardiovascular disease, aspirin at a dose of 100 mg daily significantly reduced the risk of serious vascular events by 12% compared to placebo, though it was associated with a 29% increased risk of major bleeding events.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
